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G enetic testing for cancer susceptibility is an appli-cation of biotechnology that has the potential bothto improve the psychosocial and physical well-
being of the population and to cause significant psychoso-
cial and physical harms.' In spite of the uncertain value of
genetic testing, it has captured the interest of biotechnol-
ogy companies, researchers, health care providers, and the
public. As more tests become feasible, pressure may in-
crease to make the tests available and reimbursable. Both
the benefits and harms of these tests lie not as much in the
tests themselves, as in their power to predict or alter the
future. The value of the tests does not derive from the in-
formation per se, but from the ability to communicate ef-
fectively the information to patients and providers, and
the behavioral responses of patients, providers, and others
to this information.
The recent marketing of genetic tests for breast can-
cer^ focuses attention on the health policy questions at the
intersection of cancer detection and treatment, and genetic
technologies. In both areas, health policy decisions to use
new technologies increasingly rely on empirical data, but
are also more responsive to public and professional senti-
ment.^ At times, these approaches yield conflicting policy
positions. Although there may be a tendency to defer the
introduction of new technologies until sufficient data about
risks and benefits are available, there may also be a ten-
dency to respond to public and professional requests to
make potentially beneficial technologies available, even
though they might not have been thoroughly evaluated.
The evolving system of health care delivery in the United
States and the uncertainty about which services ought to
be paid for by a third party add to the complexity of health
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policy decisions about genetic testing for cancer suscepti-
bility.
One step taken to facilitate these health poUcy delib-
erations has been the funding of eleven studies in response
to a 1994 Request for Applications by the National Insti-
tutes of Health (NIH) on studies of genetic testing and
counseling for heritable breast, ovarian, and colon cancer
risks. These projects, along with five others, have formed
the NIH Cancer Genetics Studies Consortium (CGSC),
which is coordinated by the Ethical, Legal and Social Im-
plications Program (ELSI) of the National Human Genome
Research Institute (NHGRI). CGSC's purpose is to provide a
forum for discussion and collaboration regarding informed
consent, study design, assessment instruments, laboratory
techniques, and follow-up clinical recommendations.
The purpose of this article is to synthesize the ethical
and health policy questions that are addressed by the CGSC
projects. We then describe some of the broader health policy
issues that will not be completely addressed by the projects
in order to guide further research and health policy deci-
sion making. We argue that such policy decisions, although
data-based, also involve substantive normative issues and,
thus, that the CGSC projects are necessary, but not suffi-
cient, to develop an informed policy about clinical recom-
mendations regarding routine testing.
The scope of the CGSC projects
The CGSC projects address a broad range of clinical, psy-
chosocial, and ethical issues relevant to genetic counseling
for breast and ovarian cancer (BRCA1/BRCA2) and colon
cancer (HNPCC) susceptibility. Most projects focus on
people identified to be at increased risk of developing can-
cer because of their family histories. Some studies are as-
sessing consumer knowledge and attitudes about genetic
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testing and counseling for cancer risks in order to learn
about interest in testing as well as about needs and prefer-
ences for counseling. Other studies are examining the level
of knowledge, the intentions, and the abilities of primary
care physicians, nurses, oncologists, medical geneticists,
and genetic counselors to educate and counsel people ef-
fectively. In these studies, knowledge areas include: under-
standing the impact of family history on cancer risk; inter-
pretation of a positive or negative test; and understanding
of the limitations of available options for cancer surveil-
lance and management. Several projects are evaluating al-
ternative methods for patient and provider education and
counseling so to identify the optimal approaches. Informa-
tion gained from such studies will be valuable in designing
model protocols for patient and provider education, as well
as for informed consent and genetic counseling services."*
An additional area of emphasis within CCSC involves
evaluation of decision making about genetic testing and
the impact of disclosure of mutation status. For the latter,
key end points include comprehension of risk, psychoso-
cial well-being, functional health status, and family func-
tioning. These studies are also likely to provide insight into
whether significant problems arise with employment or
insurance for those who decide to undergo testing.
Of great interest is the impact of testing on partici-
pants' decisions about surveillance and prophylactic sur-
gery. For example, it is possible that disclosure of BRCAl
mutation status may generate anxiety that leads women to
avoid cancer screening tests.^ Analyses of health behavior
outcomes are especially complex because of Umited data
on the efficacy of available surveillance and management
options. For example, mammography may be less effec-
tive in younger women who have denser breast tissue.'
Concerns also exist that more frequent use of mammogra-
phy will increase cancer risk; however, there are no data
available to support this. Screening tests for ovarian cancer
are lacking in sensitivity and specificity for women of all
ages.'' Even the most extreme measures, such as prophy-
lactic mastectomy and oophorectomy, do not eliminate risk
entirely.^ CGSC investigators have developed consensus
documents to provide interim guidance for follow-up care
for those individuals found to have BRCAl, BRCA2, or
HNPCC mutations.' However, more data about the opti-
mal preventive and treatment strategies are needed before
more informed recommendations about genetic testing
follow-up can be developed.
Ethical issues highlighted by the CGSC projects
As the CCSC projects have progressed, a number of ethical
issues have been encountered. These include issues of in-
formed consent, privacy, and confidentiality, familial im-
plications, requests for testing children, and reproductive
issues. Although these issues are not unique to genetic test-
ing for cancer susceptibility, some characteristics of can-
cer, including the seriousness of the disorders, the unde-
fined penetrance of mutations in the general population,
and ambiguities about effective interventions, increase the
complexity of these issues. The experiences of the CGSC
projects with these issues provide a framework for consid-
ering similar issues involved in the clinical delivery of ge-
netic testing services.
Informed consent
Informed consent is not just the event of signing a docu-
ment; it is also a process. However, the document does
represent the essential content of the process. The docu-
ments of the consortium projects were reviewed by outside
consultants and discussed at the first consortium meeting.
Consortium members generally agreed that certain points
should be included in all documents. First, the voluntary
and optional nature of testing should be emphasized. Sec-
ond, participants should be told about the limitations of
testing as well as the potential benefits. These limitations
include the accuracy of current diagnostic technologies,
the fact that test results cannot provide definitive informa-
tion about whether or when cancer will develop (for ex-
ample, incomplete penetrance), and limitations in avail-
able options for prevention and surveillance. Discussion of
risks should include the potential for anxiety, altered fam-
ily relationships, stigmatization, and discrimination.'" But,
characterizing these social risks, qualitatively and quanti-
tatively, in a consent process is challenging.
The impact of the consent process on decision making
is not clear." In a randomized trial of pretest education
approaches among women with a family history of cancer,
individualized face-to-face education and counseling did
not alter testing plans.'^ However, other CCSC observa-
tions indicate that motivation to have genetic testing may
decrease as people receive more education." The goal of
the process of informed consent is to allow people to make
medical decisions about what they want, based on adequate
understanding of relevant facts, as well as on their own
values. Although surrogate markers such as comprehen-
sion and understanding or behavioral outcomes are very
important, the adequacy of informed consent should be
assessed from the perspective of the participants themselves.
There is limited data about the appropriate content and
methods for informed consent for genetic testing. These
studies will provide some of this data. In the interim, CCSC
established the Task Force on Informed Consent to con-
sider the a priori components of consent for cancer genetic
susceptibility testing.'''
Privacy and confidentiality
CGSC members acknowledged that even though informa-
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tion about cancer risk would be kept confidential by the
investigators, the potential health implications of this in-
formation increases the probability that participants would
discuss these issues with their physicians. For example, the
disclosure of the presence of a BRCAl mutation to a phy-
sician may be necessary for obtaining earlier or more fre-
quent mammograms. There was consensus that participants
should be informed that such discussions may result in in-
formation being recorded in their medical records and that
such recording would increase the chances of third parties
gaining access to test results. Additionally, even if the in-
formation is not placed in medical records, in most states,
insurers or others are not prohibited from requesting this
information directly from individuals.'' The privacy and
confidentiality issues are further complicated by consider-
ation of the familial implications discussed below.
Familial implications
The identification of a cancer susceptibility mutation has a
potential impact on family relationships. Further, the fa-
milial issues complicate informed consent and follow-up
counseling, as well as privacy and confidentiality. This is-
sue was faced by the investigators who wanted to recruit
family members who were at increased risk to have muta-
tions because their relatives had identified mutations. Al-
though this issue has been acknowledged in previous ge-
netic testing programs that focused on reproductive deci-
sion making,'* it has greater significance in genetics for
susceptibility to adult-onset diseases. If general population
testing should occur in the future, this will become more
of an issue because every new person identified will also
likely have other family members who are at increased risk.
Participants need to consider whether to inform other
family members of their own risk, because this informa-
tion has implications for them as well. Disclosing such in-
formation may be a means of securing social support, but
it can also increase the risk of breaches of confidentiality.
Some participants may decide that they do not want their
relatives or friends to know their test results or may choose
not to be tested because of fear of disclosure.'^ Thus, coun-
seling about this issue should occur prior to testing. There
was consensus among CGSC investigators that the poten-
tial value of the information to relatives is sufficient to
encourage participants to inform relatives in most circum-
stances. However, in some instances, the presence of com-
plex familial relationship could lead a physician to recom-
mend that information not be shared.
When participants want to disclose this information
to family members, they may be uncertain about how to
proceed. Thus, one important part of counseling may be
to discuss possible strategies for effective communication
with family members about test results. It may be useful to
develop pamphlets or letters that give suggestions to par-
ticipants about how to communicate this information, as
well as to provide specific pamphlets or letters that could
be given to relatives.
Nevertheless, the discussion of test results with other
family members might not always be well received. In one
testing strategy, generations within a family are tested in a
hierarchical manner, so the result in a member of an older
generation would clarify the need for testing the younger
generation. Because some relatives may feel that their pri-
vacy has been violated if their names are given to investi-
gators, it may be better for the initial contact to come from
the family member. The other family members may not be
aware of their increased personal risk, or may not want to
know. Although not informing such individuals protects
the interests of those who wish not to know, it may be at
the expense of those who want to be tested. Additionally,
informing an individual that he/she has a family history of
a gene mutation is not the same as having a genetic test.
The family member still has an opportunity to decide
whether to pursue further testing to evaluate his/her per-
sonal risk.
In the protocols that are not hierarchical, a different
problem emerges. Adults might want to be tested for can-
cer susceptibilities for which their parents have not been
tested, because the parents did not want to know their sta-
tus. In this case, a positive test in the adult son/daughter
would imply that the parent is also positive. Although ef-
forts could be made not to inform the parent, this may be
difficult. This information might inadvertently be shared
with the parent or even with third parties, including insur-
ance companies. Although it may be tempting to err on the
side of respecting the wishes of the parent and not to test
their children, this would allow the parent to overrule the
personal decision of the adult child. There is no legal and
medical precedent for requiring parental permission in or-
der for competent adults to make health care decisions. If
such a situation were to arise, it would be desirable to en-
gage in detailed conversations with all parties, if possible.
As with many issues in clinical ethics, nonconfrontational
exploration of concerns with the involved parties can lead
to satisfactory compromise and resolution of the conflict.'*
The CGSC studies may provide data on the conflicts be-
tween adults and their parents about testing.
Another approach to identifying research participants
would be subsequent to the testing of surgical pathology
tissue samples, without prior consent. Although none of
the CGSC projects uses this approach, the familial impli-
cations are even greater, inasmuch as the patient does not
have the opportunity to consider these issues prior to re-
ceiving the results. Even though these issues can be ad-
dressed by prior consent, it is also possible to test patho-
logical specimens from deceased patients. In this setting, it
is less clear who has authority to consent or how disagree-
ments between family members should be resolved."
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Requests for testing of children
A consensus is emerging that genetic testing for adult-on-
set diseases should generally be deferred until adulthood.^"
Children cannot provide consent, so they must rely on sur-
rogate decision-makers. Children may be uniquely vulner-
able to the psychosocial risks of testing because they are
undergoing the developmental processes of acquiring a self-
image and independence. The central issue is whether the
potential benefits of testing outweigh the potential harms.
Although parents are usually in the best position to make
such determinations, there are little data about the impact
of such information on children and their families.
In the CGSC projects, children have been excluded
from testing. However, individuals who are found to have
mutations may still request testing for their children. Pre-
liminary reports suggest that one of the reasons people cite
for requesting genetic tests for themselves is to determine
whether they could have transmitted a gene to their chil-
dren.^' It is possible that some parents may also want to
have their children tested. The potential benefits and risks
should be discussed with participants who express such an
interest, but it is appropriate to defer clinical testing in
children until these benefits and risks are more clearly de-
fined. The CGSC projects may gather data on the amount
of interest expressed by parents in having their children
tested. Further research is needed to delineate better the
benefits and risks of such testing in children.^^
Reproductive issues
In rare instances, individuals who are found to have a can-
cer-associated mutation may express interest in prenatal
testing for cancer risks. Parents may not want to have a
child with the same disease that they could develop. This
raises fundamental questions regarding the appropriate-
ness of prenatal diagnosis and pregnancy termination in
such cases.^ ^ Given the lack of information about the im-
pact of such testing on adults, it is premature even to con-
sider prenatal testing for cancer risks. However, it will be
important to document any interest in prenatal testing for
cancer risks during the course of the CGSC projects. Fur-
ther, the studies may collect data about the impact of test-
ing on other reproductive decision-making issues.
Health policy implications of the CGSC projects
The clinical utility of genetic testing
One of the primary goals of the CGSC projects is to help
inform policy decisions about such testing in high-risk popu-
lations and, to a lesser extent, in the general population.
The studies will provide data on the psychosocial safety
and efficacy of testing. However, a number of method-
ological issues will create difficulties in drawing inferences
from these studies to health policy decisions for routine
testing in the general population.
One significant difference between these studies and
routine testing is that most of the CGSC projects primarily
involve high-risk families. Findings in these studies may
not be applicable to the population at large, where the ma-
jority of families are at low risk. The psychosocial benefits
and harms may be quite different for individuals who do
not consider themselves to be at high risk or who have had
no prior experience with the disease.
A second high-risk group that will emerge during these
studies are relatives of those identified with mutations. In
contrast to people self-identified as members of high-risk
families, this second group is less likely to have had previ-
ous personal experience with cancer and less likely to have
perceived themselves to be at high risk. Such individuals
may have less interest in testing and may have different
attitudes and behaviors in response to test results.
Furthermore, even among high-risk families, the study
participants may not be representative of this population.
Participants who have the motivation to enroll in the stud-
ies may be a subset of people who have different attitudes
and behavioral responses than high-risk people who do
not participate. Moreover, the highly structured nature of
the counseling and educational interventions may yield
results that are different when compared with those from
the less structured approach that is likely to be provided in
routine practice. Finally, the evaluative assessments that
are part of the study may have an impact on participants'
attitudes or behaviors about cancer genetic testing.
Just as with pharmaceutical testing, where phase I and
II trials must show safety and efficacy and phase III trials
demonstrate clinical utility, the data from these initial can-
cer studies are necessary but insufficient to show clinical
utility. '^' Nevertheless, the CGSC studies will lay the foun-
dation for examination of clinical utility, which will be
necessary to make policy decisions about cancer genetic
testing. These studies might have to be conducted in a more
routine setting, such as a primary care physician's office.
Whereas research settings may provide more extensive
counseling and support services, these services may be
impractical in daily routine because of constraints on time,
personnel, training, and reimbursement. Although studies
in routine clinical settings could expose participants to some
risk, the data gathered would be important in deciding
whether such routine testing is safe and effective.
Routine testing in a managed care environment
Currently, decisions about reimbursement are generally
made arbitrarily by third-party payers." There are few data
about how payers will perceive genetic testing for cancer
risks. Managed care organizations (MCOs) are likely to be
interested in genetic testing programs that result in cost
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savings or that have greater cost-effectiveness ratios. It is
also possible that they will not provide the intensive edu-
cation and counseling associated with testing. In other
words, MCOs may fund the test itself, but may be less
likely to fund the counseling that should accompany such
testing. MCOs may also be reluctant to refer patients for
psychological support and genetic counseling. Although
physicians could be trained and given the time to counsel
patients, it is also possible that they will be expected only
to provide testing, with neither adequate training nor coun-
seling time. These concerns are speculative, but they point
to a potential that the benefits of testing, as determined in
research studies, may not accrue in a managed care envi-
ronment.^' Thus, studies of the provision of these services
within the context of managed care constraints may be
helpful.
Another influence on clinical practice is marketing strat-
egies by commercial laboratories that may promote testing
to practitioners or directly to patients. Although most pro-
fessional statements issued suggest that cancer genetic test-
ing should be limited to institutional review board (IRB)
approved, hypothesis-driven programs,^^ one statement ac-
knowledges that clinical testing may occur outside the re-
search setting,^^ and some commercial laboratories are en-
couraging clinicians to provide testing more broadly.^' It is
possible that MCOs will require stronger evidence of ben-
efit prior before deciding to fund testing and counseling.
As long as the testing cost is greater than $1,000 per test, a
lack of third-party payment may slow the initial diffusion
of genetic testing for breast cancer. However, this may only
be a temporary situation, because the costs are expected to
decline.
Nevertheless, the tension between commercial inter-
ests in promoting testing and managed care interests in
minimizing costs point to a broader issue. Although policy
decisions might be determined by the strength of these com-
peting interests, ideally, decisions about third-party fund-
ing should follow from standard-of-care determinations.
The decision about whether the benefits of testing out-
weigh the cost, while based on data, is sufficiently subjec-
tive to count as a social decision. Such public health deci-
sions should be made with input from groups with other
than strong financial interests.^"
Cost-utility data and normative evaluations
It is possible that genetic testing for cancer susceptibility
will save direct medical costs because of reduced morbid-
ity and mortality.'^ However, this may take years to estab-
lish definitively and, in fact, might not be found to be the
case. The lack of evidence of cost savings, however, does
not mean that such services are not a worthwhile use of
resources, because saving lives usually costs money. One
approach to assessing explicitly the impact of medical re-
sources on society is cost-utility analysis (CUA).'^ CUA in-
volves a determination of some combination of direct and
indirect medical and nonmedical costs. These costs are then
compared with some nonmonetary utility, such as mea-
sures of well-being, reduction of symptoms, quality-adjusted
life years, and so forth. Cost-utility analyses and their in-
terpretations have a large normative component that does
not marginalize their importance; rather, it emphasizes the
complexity of such evaluations.
One normative aspect of CUA is determining which
utilities are the appropriate outcomes measures. For can-
cer susceptibility genetic testing, candidate measures could
include decreased incidence of cancer, decreased morbid-
ity and mortality from cancer, increased early cancer de-
tection, improved cancer surveillance and preventive be-
haviors, improved well-being and quality of life, and indi-
vidual satisfaction. However, outcomes can be valued dif-
ferently. For example, some may consider improved well-
being and quality of life to be a sufficient benefit, while
others may argue that there should be a demonstration of
decreased morbidity and mortality in order for society to
invest the same resources.
Fven if some agreement is reached about which out-
comes should be valued, there could still be differing as-
sessments of whether the benefits are worth the cost. People
who are at high risk, insurers, and society may each be
willing to spend different amounts of money to achieve
the same goal. There is no defined mechanism for solicit-
ing broad input or particular process to decide such issues.
This is not a unique problem for cancer genetic testing, but
one that must be faced by the health care system as a whole.
However, the frenetic pace of genetic discoveries and the
potential for psychosocial harms has illuminated the present
need to develop a national mechanism for genetics policy
development.
Similar suggestions have been made previously,^' but
recendy more explicit recommendations were made in a
report by Mark Rothstein et al. to NIH and to the Depart-
ment of Energy regarding the Human Genome Project^''
and in a report by the ELSI Task Force on Genetic Test-
ing." The Rothstein report proposes a federally chartered
Advisory Committee on Genetics and Public Policy at the
level of the secretary of the Department of Health and
Human Services (DHHS). This committee would encour-
age participation of the public, professional societies, gov-
ernment regulatory agencies, and the research community
in addressing issues of genetics policy and practice, legisla-
tive and regulatory policy, professional education, public
education, access to and quality of genetic services, pri-
vacy and confidentiality, and discrimination based on ge-
netic information. The committee would consist of fifteen
to eighteen members with broad expertise and would es-
tablish task forces, as needed, to address emerging issues.'*
The ELSI Task Force on Genetic Testing has made a
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similar recommendation that the secretary of DHHS cre-
ate an Advisory Committee on Cenetic Testing that would
also include participation of all stakeholders. This com-
mittee would have the following goals:
[that] (a) the introduction of new genetic tests into
clinical use [be] based on evidence of their analytical
and clinical validity, and utility to those tested; (b)
all stages of the genetic testing process in clinical labo-
ratories meet quality standards; (c) health providers
who offer and order genetic tests have sufficient com-
petence in genetics and genetic testing to protect the
well-being of their patients; and (d) there be contin-
ued and expanded availability of tests for rare ge-
netic diseases.^^
Such committees have the potential to allow the clinical
integration of genetic testing into the clinical practice of
medicine in a deliberative manner. They both call for deci-
sion making by relevant stakeholders, and acknowledge
that decisions about clinical utility include normative de-
liberations. Whether such committees achieve their goals
will depend on the willingness of their members to con-
front the ethically volatile issues involving prioritization of
genetic services and to reach consensus. Additionally, at
the state level, health departments could play a more ac-
tive role in obtaining additional public input and in adapt-
ing national guidelines to meet local needs and conditions.
One example of this approach is the Advisory Committee
to the Maryland Newborn Screening Program, which was
designed to provide a forum for public review of state new-
born screening policy decisions.^*
Future research directions in cancer susceptibility
testing
Although the current CCSC projects are not designed to
answer all of the policy questions that must be considered
prior to wider availability of cancer genetic testing, they
will contribute necessary data. Civen the ultimate goal of
informing health policy, it is important to consider how
additional data can be obtained from the existing projects
or through further longitudinal study. Supplementary data
will also need to be collected in future studies of clinical
utility. We recommend that the following issues be ad-
dressed.
pants would still consider the test results to be valuable in
structuring their lives. One long-term question is how those
individuals who develop breast or colon cancer will per-
ceive the experience of genetic testing. It is possible that
those in whom an altered gene is identified will be more
emotionally prepared when they are diagnosed with can-
cer. By contrast, those whose tests do not show an altered
gene may feel misled. Additionally, data about long-term
adverse effects that might be attributable to genetic testing
(for example, loss of insurance or employment) will be
important in determining what additional privacy and dis-
crimination legislation is necessary.
Measure the long-term physical effects of testing
Even though data on the long-term physical effects of test-
ing can be obtained from retrospective outcomes studies,
it would be valuable to develop mechanisms to encourage
participants in genetic testing studies to consider prospec-
tive enrollment in longer term studies of prevention, sur-
veillance, and treatment. In anticipation that such studies
will soon be implemented, the consent process for current
studies should ask permission for other investigators to
contact participants to inform them of other studies that
become available. This would represent a unique dimen-
sion of the informed consent process, because the subject's
participation is usually kept from third parties. However,
safeguards to ensure that third-party requests have legiti-
mate purposes could be provided by requiring preliminary
review by the NHGRI ELSI program in addition to the
usual review by IRBs.
Develop a mechanism for collecting long-term
information
Individuals who believe they have experienced adverse
events could provide information to a central registry, simi-
lar to the Eood and Drug Administration program for re-
porting adverse reactions to drugs. However, a system
would have to be developed for verifying adverse events.
More important, problems would arise with ascertainment
bias. A prospective epidemiological study of the long-term
physical and psychosocial outcomes of participants who
have been tested is optimal. The development of such a
program would require cooperation among participants,
current investigators, and funding agencies.
Collect data on the long-term psychosocial effects of
testing
Some issues, such as altered perceptions of self, anxiety, or
other attitudinal and behavioral changes, may evolve over
time. For example, even if genetic testing results in initial
psychosocial distress, it is possible that, over time, partici-
Collect data on personnel time and approaches to
consent and counseling
An important step in understanding the costs and feasibil-
ity of genetic testing programs will be the collection of
data regarding the personnel costs associated with obtain-
ing consent and with providing counseling. Even though
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the CCSC projects are not designed to provide precise data
for a rigorous cost analysis, it will be possible to make
estimates of crude costs.
Assess MCOs' clinical services and counseling and
their effectiveness
Research is needed to assess the willingness of MCOs to
provide a range of routine clinical services and counseling,
and to assess the effectiveness of these services and coun-
seling. These data are necessary to understand whether the
benefits and harms of fiscally supported research programs
will occur in the routine health care setting.
Research familial implications
More conceptual and empirical research is needed about
the familial implications of susceptibility testing. The CCSC
projects are identifying a range of ethical and psychologi-
cal issues about the complexities of informing friends and
relatives. These issues need more exploration prior to de-
veloping clinical recommendations about cancer genetic
testing.
Collect data on children
Data need to be collected about participants' interests in
having their children tested, and, more important, about
the physical and psychosocial impact of testing children.
The benefits and harms of testing in children are uncer-
tain. As more data become available on the impact of test-
ing on adults, that information will be important in de-
signing studies to address these issues with respect to chil-
dren.
Research the implications of prenatal and
preimplantation diagnosis
Eurther conceptual and empirical research is needed about
how genetic susceptibility testing might be used for prena-
tal diagnosis and preimplantation diagnosis. Even though
these issues are not part of the CCSC protocols, they in-
volve potential future uses of technologies that some people
would consider valuable. Thus, more attention should be
given to these issues to develop ethical and policy posi-
tions.
Conclusions
The CCSC projects are integral to policy making for ge-
netic testing for cancer risks because they will provide im-
portant data about the safety and efficacy of such testing.
Additional data is needed regarding the long-term physical
and psychosocial impact of genetic testing. But, even with
CGSC studies, many policy questions about cancer testing
related to clinical utility and implementation will remain
unanswered: Who will provide the testing and counseling
outside research settings?; How will they be trained?; Who
should have access to testing and test results?; and How
will testing and counseling be reimbursed? Additionally,
the broader issue of the value of such programs within the
context of other health services needs to be evaluated. These
questions should be addressed in a systematic fashion prior
to the routine utilization of such testing.
The resolution of these issues cannot be provided solely
through the CCSC projects. It will require the participa-
tion of professionals, the public, and policy-makers to de-
termine whether to expend fiscal resources to provide can-
cer genetic services that may improve the quality of the
lives of individuals in our society.
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